NMD PHARMA
NMD Pharma is a clinical-stage biotech company that delivers life-transforming therapies for people living with neuromuscular diseases. They use ClC-1 Cl- ion channel inhibitors to treat neuromuscular diseases. Their translational muscle electrophysiology platform leverages in-depth knowledge of muscle physiology and muscular disorders to identify and develop first-class therapeutics for neuromuscular diseases that are unmet medically.
NMD PHARMA
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2015-01-01
Address:
Risskov, Midtjylland, Denmark
Country:
Denmark
Website Url:
http://www.nmdpharma.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
76.03 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Content Delivery Network Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS YouTube
Similar Organizations
Noema Pharma
Noema Pharma is a biotech company that develops therapies to address disabling symptoms in conditions of the brain and nervous system.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Investors List
Lundbeckfonden Emerge
Lundbeckfonden Emerge investment in Venture Round - NMD Pharma
Novo Holdings
Novo Holdings investment in Venture Round - NMD Pharma
Inkef
Inkef investment in Venture Round - NMD Pharma
Roche Venture Fund
Roche Venture Fund investment in Venture Round - NMD Pharma
Jeito Capital
Jeito Capital investment in Venture Round - NMD Pharma
Inkef
Inkef investment in Series A - NMD Pharma
Novo Holdings
Novo Holdings investment in Series A - NMD Pharma
Roche Venture Fund
Roche Venture Fund investment in Series A - NMD Pharma
Lundbeckfonden Emerge
Lundbeckfonden Emerge investment in Series A - NMD Pharma
CAPNOVA
CAPNOVA investment in Venture Round - NMD Pharma
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-10 | NMD Pharma appoints Dr. Jorge A. Quiroz as EVP, Chief Medical Officer |
Official Site Inspections
http://www.nmdpharma.com Semrush global rank: 5.1 M Semrush visits lastest month: 1.61 K
- Host name: 198.49.23.145
- IP address: 198.49.23.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "NMD Pharma"
NMD Pharma
Our team is comprised of experts and leaders from around the world dedicated to developing novel treatments to improve muscle function and quality of life of patients with neuromuscular …See details»
Management team - NMD Pharma
Dan joined NMD Pharma as Senior Vice President of Corporate and Commercial Strategy in June 2023. Dan has 25 years of strategic commercial experience in the pharmaceutical and biotech industries in a variety of large, medium and …See details»
NMD Pharma - Crunchbase Company Profile & Funding
View contacts for NMD Pharma to access new leads and connect with decision-makers. NMD Pharma is a clinical-stage biotech company that delivers life-transforming therapies for people …See details»
NMD Pharma A/S - LinkedIn
NMD Pharma is the leading company utilizing ClC-1 Cl- ion channel inhibitors for neuromuscular diseases and currently has one clinical-stage product candidate for the treatment of myasthenia...See details»
NMD Pharma Receives IND Clearance from the FDA to initiate
Aarhus, Denmark, 18 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with severe neuromuscular …See details»
NMD Pharma Company Profile 2024: Valuation, …
Operator of a clinical-stage biotech company intended to design drugs and therapeutics for the treatment of neuromuscular disorders.See details»
NMD Pharma Receives IND Clearance from the FDA to initiate a …
Aarhus, Denmark, 18 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with severe neuromuscular …See details»
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b …
Aarhus, Denmark, 22 March 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular …See details»
About NMD Pharma — NMD Pharma
NMD Pharma is a clinical-stage biotech company founded with a focus to deliver life-transforming therapies for people living with neuromuscular diseases.See details»
NMD Pharma Raises €35 Million in a new Financing
Aarhus, Denmark, 15 February 2022 – NMD Pharma A/S, a clinical stage biotech company developing first in class, small molecule CLC-1 inhibitors for neuromuscular disorders, today …See details»
NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with …
Nov 18, 2024 · NMD670 is a first-in-class small molecule inhibitor of the skeletal muscle specific chloride ion channel 1 (CIC-1). NMD Pharma has demonstrated that CIC-1 inhibition amplifies …See details»
NMD Pharma - Craft
NMD Pharma is a drug discovery company that develops treatments of neuromuscular disorders. It strengthens neuromuscular transmission and muscle function. NMD Pharma $50.31 m in …See details»
NMD Pharma Raises €75 Million (~$80 million) in a Series B …
Aarhus, Denmark, 15 November 2023 – NMD Pharma A/S, a clinical-stage biotech dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, …See details»
PRESS RELEASE NMD Pharma initiates Phase II trial of NMD670 in …
Ch with a focus on regulation of skeletal muscle excitability under physical activity. NMD Pharma has built a world-leading muscle electrophysiology platform leveraging its in-depth know-how …See details»
NMD Pharma expands its US presence - GlobeNewswire
Aarhus, Denmark, 3 May 2022 – NMD Pharma A/S, a clinical stage biotech company developing first in class, small molecule ClC-1 inhibitors for neuromuscular disorders, today announces …See details»
Press releases - NMD Pharma
Nov 15, 2023 · NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle SocietySee details»
NMD Pharma Receives IND Clearance from the FDA to initiate a …
Jun 18, 2024 · Founded by two patients who are driven to expedite drug delivery to people who live with CMT, the 501(c)(3) federal tax-exempt organization is supported by personal and …See details»
NMD Pharma Publishes Comprehensive Data Package for …
Aarhus, Denmark, 21 March 2024 – NMD Pharma A/S, a clinical-stage biotech dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, …See details»
Pipeline - NMD Pharma
We are working to develop novel small molecule inhibitors of skeletal muscle-specific ClC-1 ion channels that can be applied to a large range of clinical indications and orphan human diseases.See details»